
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is advancing its clinical-stage pipeline with a focus on one-time gene therapies targeting neurodegenerative diseases, specifically through its lead candidate, PBFT02. The company's amended protocol for trial design presents an opportunity for earlier intervention, potentially enhancing the treatment's efficacy, while the anticipation of regulatory alignment for accelerated approval could shorten trial timelines. Furthermore, encouraging biomarker data and the strategic enrollment of patients in Cohort 3 may accelerate overall progress, positioning Passage Bio favorably in the competitive landscape within the genetic medicines sector.
Bears say
Passage Bio Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays in clinical timelines and emerging safety signals associated with its early gene therapy programs. The complexity of manufacturing AAV-based gene therapy products presents additional challenges, particularly in ensuring sufficient production capacity, which could lead to constrained financial forecasts. Additionally, historical setbacks in the gene therapy sector highlight the possibility of unforeseen safety issues that may negatively impact market sentiment towards Passage Bio.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares